From this week, the former Royal Eye Hospital, now known as Citylabs, will be following a competitive exercise now entering into its next stage of redevelopment by the chosen Manchester developer, Bruntwood. Once the building is completed in early 2014, it will be operated by Manchester Science Parks.
In this building will be 100,000 ft.² of purpose-built laboratories and workshops and offices to enable a number of healthcare companies to develop and trial new systems, devices and diagnostics which are designed to help improve the care of patients.
ICON, a major global clinical trials company, already leases the clinical trials unit on Upper Brook Street from CMFT. From June they will further increase their clinical trials capacity in Ward 27 on our site, to create one of the largest early phase clinical trials units in the country and this will create new opportunities for us to obtain more trials business. ICON will move into Citylabs when it opens.
Also taking a lease in Citylabs is The Manchester College, who are the largest further education provider in the UK and a leading College. The facility will enhance their offer for training and qualifications. The CMFT Charity Team will relocate, enabling for the first time a location for interaction with our corporate and individual donors to support our Charities. TRUSTECH who provide our innovation services and are helping us to develop new technologies to improve the services for patients, will also be taking a lease in the building. Citylabs will create opportunities for new collaborations and increased numbers of clinical trials and the Trust will deliver a benefit into the local economy through increased jobs and business opportunities.
The medical technology development centre (MedTECH Centre) that is currently based on Manchester Science Park, is operated in a joint-venture with CMFT, Manchester Science Parks and TRUSTECH , hopes to relocate into Citylabs.
It already houses 11 small and growing companies and these include the Trust’s own first two spin out companies Laprotech and Rapid Rhythm Ltd.
The new partnership between the hospital and the developer is enabling us to create a fantastic new facility that will further enhance our reputation as one of the country’s leading translational research hospitals.